Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)
Condition(s):Hodgkin LymphomaLast Updated:September 21, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Hodgkin LymphomaLast Updated:September 21, 2023Completed
Condition(s):Hodgkin’s LymphomaLast Updated:November 3, 2020Completed
Condition(s):Hodgkin Lymphoma, Adult; Hodgkin Disease Recurrent; Hodgkin Disease Refractory; Hodgkin Disease, PediatricLast Updated:April 5, 2023Active, not recruiting
Condition(s):Hodgkin’s DiseaseLast Updated:July 21, 2017Completed
Condition(s):Hodgkin’s LymphomaLast Updated:May 28, 2020Completed
Condition(s):Classical Hodgkin LymphomaLast Updated:July 23, 2018Unknown status
Condition(s):Relapsed Hodgkin Lymphoma; Refractory Hodgkin LymphomaLast Updated:March 4, 2024Recruiting
Condition(s):Hodgkin LymphomaLast Updated:September 13, 2018Completed
Condition(s):Obstructive Sleep Apnea; Hodgkin LymphomaLast Updated:March 18, 2024Active, not recruiting
Condition(s):Hodgkin Lymphoma SurvivorLast Updated:December 28, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.